Latanoprost more cost-effective than the rest

Article

Latanoprost offers a more cost-effective strategy for the treatment of glaucoma than either dorzolamide or brimonidine.

Latanoprost offers a more cost-effective strategy for the treatment of glaucoma than either dorzolamide or brimonidine, according to a study published in the February issue of the Canadian Journal of Ophthalmology.

Jean Lachaine and colleagues from the University of Ottawa Eye Institute, Ottawa, Canada conducted an economic analysis of the cost-effectiveness of prostaglandin analogues. Latanoprost was compared with timolol, dorzolamide and brimonidine, while travoprost was compared with timolol separately.

Compared with latanoprost, dorzolamide was not a cost-effective strategy. Compared with brimonidine, latanoprost provided a higher intraocular pressure (IOP) reduction with an incremental cost-effectiveness ratio of $16.17. However, the additional IOP reduction with latanoprost was obtained at a cost higher than the average cost per mmHg reduction obtained with brimonidine. Compared with timolol, latanoprost had a positive incremental cost-effectiveness ratio of $34.48 and $39.06, respectively.

As a first-line treatment for glaucoma, latanoprost is a more cost-effective strategy than dorzolamide and brimonidine. Latanoprost and travoprost are more effective than timolol but also more expensive. For those for whom timolol is not contraindicated, it may be preferable, from a cost-effectiveness point of view, to initiate treatment with timolol and reserve the prostaglandin analogues as an alternative treatment or as an add-on therapy for patients who do not achieve the required results with timolol alone.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
© 2025 MJH Life Sciences

All rights reserved.